Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label
pharmaphorum
JANUARY 12, 2021
Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes. It says Farxiga will reach peak sales of $9 billion in 2028, with Jardiance forecast to reach $4.6
76 
Let's personalize your content